Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study
Restricted accessResearch articleFirst published online February 1, 2022
Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study
Subjective cognitive decline (SCD) might occur at the early stages of dementia. Individuals with SCD have an increased risk of subsequent objective cognitive decline and greater rates of progression to dementia.
Objective:
We aimed to explore the associations between SCD and cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) pathology in cognitively normal individuals.
Methods:
A total of 1,099 cognitively normal elders with available data on CSF biomarkers of AD pathology (Aβ42, P-tau, and T-tau) were included in our analysis. Linear regression was used to examine the associations of SCD status and SCD severity with CSF biomarkers. Additionally, a review was conducted to discuss the associations between SCD and CSF biomarkers of AD pathology.
Results:
After adjustments for covariates, SCD and SCD severity showed significant associations with CSF Aβ42 (SCD: β= –0.0003, p = 0.0263; SCD severity: β= –0.0004, p = 0.0046), CSF T-tau/Aβ42 ratio (SCD: β= 0.1080, p = 0.0064; SCD severity: β= 0.1129, p = 0.0009) and CSF P-tau/Aβ42 ratio (SCD: β= 0.0167, p = 0.0103; SCD severity: β= 0.0193, p = 0.0006) rather than T-tau and P-tau compared with cognitively normal individuals. In the review, a total of 28 studies were finally included after reviewing 174 articles. CSF Aβ42 was lower in SCD than cognitively normal (CN) individuals, but higher than those with objective cognitive decline. However, CSF tau pathology showed no difference between SCD and CN.
Conclusion:
The results indicated that pathophysiological changes in CSF Aβ pathology occurred in individuals with SCD, which provide new insights into early intervention of AD.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
6.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr., KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
7.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr., KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
8.
JessenF, AmariglioRE, BuckleyRF, van der FlierWM, HanY, MolinuevoJL, RabinL, RentzDM, Rodriguez-GomezO, SaykinAJ, SikkesSAM, SmartCM, WolfsgruberS, WagnerM (2020) The characterisation of subjective cognitive decline. Lancet Neurol19, 271–278.
9.
RabinLA, SmartCM, AmariglioRE (2017) Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol13, 369–396.
VisserPJ, VerheyF, KnolDL, ScheltensP, WahlundLO, Freund-LeviY, TsolakiM, MinthonL, WallinAK, HampelH, BürgerK, PirttilaT, SoininenH, RikkertMO, VerbeekMM, SpiruL, BlennowK (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol8, 619–627.
12.
OlssonB, LautnerR, AndreassonU, ÖhrfeltA, PorteliusE, BjerkeM, HölttäM, RosénC, OlssonC, StrobelG, WuE, DakinK, PetzoldM, BlennowK, ZetterbergH (2016) CSF andblood biomarkers for the diagnosis of Alzheimer’s disease: Asystematic review and meta-analysis. Lancet Neurol15, 673–684.
13.
XuW, TanL, SuBJ, YuH, BiYL, YueXF, DongQ, YuJT (2020) Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology in cognitively intact older adults: The CABLE study. Alzheimers Dement16, 1146–1152.
14.
JessenF, AmariglioRE, van BoxtelM, BretelerM, CeccaldiM, ChételatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotinA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
15.
MolinuevoJL, RabinLA, AmariglioR, BuckleyR, DuboisB, EllisKA, EwersM, HampelH, KlöppelS, RamiL, ReisbergB, SaykinAJ, SikkesS, SmartCM, SnitzBE, SperlingR, van der FlierWM, WagnerM, JessenF (2017) Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement13, 296–311.
16.
GiffordKA, LiuD, RomanoR, 3rd, JonesRN, JeffersonAL (2015) Development of a subjective cognitive decline questionnaire using item response theory: A pilot study. Alzheimers Dement (Amst)1, 429–439.
17.
JormAF, ChristensenH, KortenAE, HendersonAS, JacombPA, MackinnonA (1997) Do cognitive complaints either predict future cognitive decline or reflect past cognitive decline? A longitudinal study of an elderly community sample. Psychol Med27, 91–98.
18.
RamiL, ForteaJ, BoschB, Solé-PadullésC, LladóA, IranzoA, Sánchez-ValleR, MolinuevoJL (2011) Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis23, 319–326.
19.
LeoniV, SolomonA, Lövgren-SandblomA, MinthonL, BlennowK, HanssonO, WahlundLO, KivipeltoM, BjörkhemI (2013) Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: Candidate marker of brain health. J Alzheimers Dis36, 739–747.
20.
JessenF, SpottkeA, BoeckerH, BrosseronF, BuergerK, CatakC, FliessbachK, FrankeC, FuentesM, HenekaMT, JanowitzD, KilimannI, LaskeC, MenneF, NestorP, PetersO, PrillerJ, ProssV, RamirezA, SchneiderA, SpeckO, SpruthEJ, TeipelS, VukovichR, WesterteicherC, WiltfangJ, WolfsgruberS, WagnerM, DüzelE (2018) Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimers Res Ther10, 15.
21.
MiebachL, WolfsgruberS, PolcherA, PetersO, MenneF, LutherK, IncesoyE, PrillerJ, SpruthE, AltensteinS, BuergerK, CatakC, JanowitzD, PerneczkyR, UtechtJ, LaskeC, BuchmannM, SchneiderA, FliessbachK, KalbhenP, HenekaMT, BrosseronF, SpottkeA, RoyN, TeipelSJ, KilimannI, WiltfangJ, BartelsC, DüzelE, DobischL, MetzgerC, MeiberthD, RamirezA, JessenF, WagnerM (2019) Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res Ther11, 66.
22.
LiguoriC, PlacidiF, IzziF, SpanettaM, MercuriNB, Di PucchioA (2020) Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer’s disease course. Alzheimers Res Ther12, 5.
23.
SelnesP, AarslandD, BjørnerudA, GjerstadL, WallinA, HessenE, ReinvangI, GrambaiteR, AuningE, KjærvikVK, Due-TønnessenP, StensetV, FladbyT (2013) Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment. J Alzheimers Dis33, 723–736.
EliassenCF, ReinvangI, SelnesP, GrambaiteR, FladbyT, HessenE (2017) Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. Brain Behav7, e00776.
26.
WolfsgruberS, PolcherA, KopparaA, KleineidamL, FrölichL, PetersO, HüllM, RütherE, WiltfangJ, MaierW, KornhuberJ, LewczukP, JessenF, WagnerM (2017) Cerebrospinal fluid biomarkers and clinical progression in patients with subjective cognitive decline and mild cognitive impairment. J Alzheimers Dis58, 939–950.
27.
Filipek-GliszczyńskaA, BarczakA, BudziszewskaM, MandeckaM, GabryelewiczT, BarcikowskaM (2018) The Erlangen Score Algorithm inthe diagnosis and prediction of the progression from subjectivecognitive decline and mild cognitive impairment to Alzheimer-typedementia. Folia Neuropathol56, 88–96.
28.
RizziL, Maria PortalM, BatistaCEA, MissiaggiaL, Roriz-CruzM (2018) CSF Aβ(1-42,) but not p-Tau(181,) differentiates aMCI from SCI. Brain Res1678, 27–31.
LiG, SokalI, QuinnJF, LeverenzJB, BrodeyM, SchellenbergGD, KayeJA, RaskindMA, ZhangJ, PeskindER, MontineTJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology69, 631–639.
34.
KarranE, MerckenM, De StrooperB (2011) The amyloid cascade hypothesis for Alzheimer’s disease: An appraisal for the development of therapeutics. Nat Rev Drug Discov10, 698–712.
35.
LongJM, HoltzmanDM (2019) Alzheimer disease: An update on pathobiology and treatment strategies. Cell179, 312–339.
36.
MosconiL, De SantiS, BrysM, TsuiWH, PirragliaE, Glodzik-SobanskaL, RichKE, SwitalskiR, MehtaPD, PraticoD, ZinkowskiR, BlennowK, de LeonMJ (2008) Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry63, 609–618.
